Antibody-Functionalized Carbon Nanotube Transistors as Biosensors for the Detection of Prostate Cancer
Abstract
During year 2 we successfully met nearly all benchmarks proposed in our statement of work. Strong team interactions (face-to-face meetings, videoconferences, numerous email communications and lab visits) allowed for useful discussions and insured rapid research progress. The Johnson group successfully fabricated, tested, and fully characterized biosensors consisting of nanotube transistors with covalently bound scFv antibodies developed by the Robinson group specific for osteopontin, one of our proof-of-concept biomarkers. We found that the sensor response was in excellent agreement with theory with a detection limit of ~ 1pg/mL, approximately 100-1000 fold more sensitive than standard ELIAS assays. This technology thus has the potential to open up biomarker detection to proteins found at very low levels in serum. This data supports our efforts to transition into testing patient samples in year 3. Our ultimate goal is the development of a prototype biosensor that will be used to retrospectively test patient samples during year 3 of this award. The research accomplishments achieved in years 1-2 have positioned us well for meeting this goal. By the end of this funding period we aim to have generated sufficient data to support the development of this sensor platform.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2011
- Accession Number
- ADA549636
Entities
People
- Alan Johnson Jr.
Organizations
- University of Pennsylvania